Home > Articles > NAMPT explained: the rate-limiting enzyme in NAD+ recycling
NAMPT explained: the rate-limiting enzyme in NAD+ recycling
Prepared by: Research Desk
Prepared by: Research Desk. Sources are linked for verification.
Most writing about NAD+ focuses on the molecules sold in capsules, such as NMN and NR. In research papers, though, one enzyme comes up again and again: NAMPT, short for nicotinamide phosphoribosyltransferase. NAMPT sits at the bottleneck of the main route cells use to rebuild NAD+. To read NAD+ research critically, it is useful to know what this enzyme does, where it is found, and how scientists measure it. This explainer covers the enzyme itself. Our NAD+ guide covers the wider NAD+ system.
What NAMPT does
NAD+ works in two ways. It carries electrons in energy metabolism, where it is recycled between NAD+ and NADH. It is also consumed as a raw material by enzyme families such as sirtuins, PARPs and CD38. When those enzymes use NAD+, they release nicotinamide as a by-product [1].
If cells could not recover that nicotinamide, they would have to make NAD+ from scratch all the time. Instead, most mammalian cells run a recycling loop, often called the salvage pathway. NAMPT carries out the first committed step:
NAMPT joins nicotinamide to a phosphoribose donor (PRPP) and makes nicotinamide mononucleotide (NMN).
NMNAT enzymes then convert NMN into NAD+.
Reviews of the field describe NAMPT as the rate-limiting enzyme of this pathway [1][2]. That means the speed of the NAMPT step largely sets how fast nicotinamide is turned back into NAD+ in many tissues.
Why "rate-limiting" matters for reading precursor research
The rate-limiting label explains a lot of the logic behind precursor research. NMN is the product of the NAMPT reaction. Supplying NMN directly therefore enters the pathway downstream of the bottleneck. Nicotinamide riboside (NR) takes a different route. Nicotinamide riboside kinases (NRKs) convert it into NMN, so it also bypasses the NAMPT step [2].
This is a biochemical rationale, not a finding about outcomes. Showing that a molecule enters the pathway past NAMPT does not show what happens to health in people. Yoshino and colleagues' 2018 review in Cell Metabolism lays out these routes and separates mechanistic reasoning from the human data available at the time [2]. Our NAD+ guide summarises what randomized human trials of precursors have measured.
Two forms of the same enzyme: iNAMPT and eNAMPT
NAMPT exists in two locations, and the naming can be confusing:
iNAMPT (intracellular NAMPT) works inside cells and runs the salvage reaction described above.
eNAMPT (extracellular NAMPT) is released from cells, notably fat tissue, and circulates in the blood.
The extracellular form was described in several research fields before scientists recognised it as the same protein. As a result, older papers may call it visfatin or pre-B-cell colony-enhancing factor (PBEF). Imai and Guarente's 2014 review discusses eNAMPT as a possible systemic signal linking tissues in NAD+ biology [1]. When searching the literature, it is worth running all three names. Some antibody-based assay kits are also still labelled "visfatin."
The 2019 eNAMPT mouse study
A widely cited mouse study by Yoshida and colleagues (Cell Metabolism, 2019) reported that eNAMPT circulates inside extracellular vesicles, the small membrane-bound particles that cells release. The study reported that levels of vesicle-contained eNAMPT in mice declined with age. It also reported that giving aged mice vesicles containing eNAMPT from young mice was associated with changes the authors interpreted as delayed aging, plus an extension of lifespan [3].
Three points matter when reading this study:
It is an animal study. Its results have not been shown in humans.
It concerns a specific vesicle-carried form of the enzyme, not NAD+ products in general.
It is research on biological mechanisms. It does not test any consumer product.
NAMPT and age-related NAD+ data
Imai and Guarente's review proposed that reduced NAMPT-mediated NAD+ synthesis may contribute to falling NAD+ in some tissues with age. They presented this as a model built mostly on animal data [1]. Human tissue data are thinner. A 2012 study by Massudi and colleagues in PLoS One measured NAD+ and markers of oxidative stress in human tissue samples and reported age-associated changes in NAD+ metabolism [4]. That study measured tissue NAD+ and related markers in a limited set of samples. It was not designed to test NAMPT as the single cause of those changes, which is a reason not to generalise one tissue finding to the whole body.
NAMPT is not a simple "more is better" enzyme
Some of the most informative NAMPT research comes from areas outside healthy aging. These studies show that higher NAMPT activity can be associated with unwanted processes, depending on the tissue:
Cellular senescence (cell and mouse studies). Nacarelli and colleagues reported in Nature Cell Biology (2019) that NAD+ metabolism governs the proinflammatory secretions of senescent cells, known as the senescence-associated secretory phenotype (SASP). Their work linked NAMPT expression in senescent cells to that inflammatory output [5].
Intestinal inflammation (human tissue and mouse studies). Gerner and colleagues reported in Gut (2018) that NAD metabolism, including NAMPT, was raised in inflamed intestinal tissue from people with inflammatory bowel disease. In mouse models, they reported that blocking NAMPT with an experimental research inhibitor reduced markers of intestinal inflammation [6].
Tumour immune evasion (cell and mouse studies). Lv and colleagues reported in Cell Metabolism (2021) that NAMPT-dependent NAD+ metabolism maintained inducible PD-L1 expression in tumour cells. PD-L1 is a protein that lets tumour cells evade immune attack [7].
Cancer and immunity (review). Navas and Carnero's 2021 review describes NAMPT as a frequent subject of cancer research because many tumour cells depend heavily on the salvage pathway. It also covers the enzyme's roles in immune responses and stem-cell biology [8].
Taken together, these papers show that NAMPT activity has effects that depend on context. The same enzyme that keeps NAD+ supply stable in normal tissue appears in research on inflammation, senescence and tumour biology. Any claim that simply "raising NAMPT" is desirable runs ahead of this literature.
How researchers measure NAMPT
Since this site focuses on lab methods, it is worth knowing that "NAMPT levels" can mean several different measurements. These measurements are not interchangeable:
Gene expression (mRNA). This shows how much NAMPT message a tissue is producing. It does not show how much active enzyme is present.
Protein amount. This is measured in tissue extracts (for example by western blot) or, for eNAMPT, in plasma or serum by immunoassay. Results depend on antibody specificity. They also depend on whether the assay captures free protein, vesicle-contained protein, or both. The vesicle finding in the 2019 mouse study shows why that distinction matters [3].
Enzyme activity. This measures how fast a sample converts nicotinamide into NMN. It is closer to function, but it is technically harder and less standardised.
Downstream metabolites. This means measuring NMN, NAD+ and related compounds. These reflect the whole pathway, not NAMPT alone. They are also affected by NAD+-consuming enzymes [1].
When a study reports a change in "NAMPT," it is worth checking which of these was measured, in which tissue or fluid, and in which species. A separate regulatory point is also relevant when marketing copy mentions the enzyme: FDA does not approve dietary supplements for safety and effectiveness before they are marketed [9]. Our regulatory overview explains how this applies to NAD+-related ingredients.
What the NAMPT literature does not tell us
None of the sources summarised here is a human trial of an intervention aimed at NAMPT. The human evidence cited on this page comes from tissue measurements [4] and from inflamed intestinal tissue [6]. The lifespan findings come from mice [3]. The mechanistic picture is well established in reviews [1][2]. How NAMPT activity relates to long-term outcomes in people is still an open question. We label study types throughout this site for exactly this reason. See how this site works for our sourcing and evidence-labelling approach.
Further reading: choosing a biochemistry book
Some readers want to go beyond single papers and understand pathways like this one in depth. A good biochemistry text makes the primary literature much easier to follow. Neutral criteria for comparing options:
Edition date. Research on extracellular NAMPT has moved quickly since the 2010s, so recent editions are more likely to reflect current naming and models.
Pathway coverage. Look for clear chapters on nucleotide metabolism, cofactor synthesis and enzyme kinetics, including how a rate-limiting step is defined.
Figures. Labelled pathway diagrams showing substrates, enzymes and products save a lot of time.
References. Texts that cite primary research let readers check claims against the original studies.
Level and format. Introductory texts suit general readers, while graduate-level texts suit lab work. Ebook versions are easier to search, and print versions are easier to annotate.
Price transparency. Compare new, used and rental pricing, and check whether online supplementary material needs a separate access code.
Our book coverage follows the same evidence-first standards as the rest of the site. Recommendations never depend on whether a link earns a commission.
Frequently asked questions
What does NAMPT stand for?
NAMPT stands for nicotinamide phosphoribosyltransferase. It is the enzyme that converts nicotinamide into NMN, which other enzymes then turn into NAD+ [1][2].
Are visfatin and NAMPT the same thing?
The extracellular form of NAMPT, called eNAMPT, was described under the names visfatin and PBEF before researchers recognised it as the same protein. Older papers and some assay kits still use those names. Searching the literature under all three terms gives a more complete picture [1].
Does more NAMPT activity always mean better health?
The published research does not support that simple view. Cell and mouse studies have linked NAMPT-dependent NAD+ metabolism to inflammatory senescent-cell secretions and to tumour immune evasion. A human-and-mouse study linked it to intestinal inflammation [5][6][7].
Last updated: 19 October 2026.
Related on this site
NAD+ explained: biochemistry, precursors, testing and human evidence
NAD+ test buyer's guide: how at-home blood tests work and compare
Reading an NAD+ test report: units, sample types and reference ranges
NAD+ books: an evidence-graded reading list on sirtuins and aging
Nicotinamide riboside research: what human trials have measured
Not medical advice. This page reports published research and regulatory records for information only.
Research-only notice: Content on this site is provided for research and educational purposes only and is not intended for human use. It is not medical advice.
Translation notice: Some content on this site may have been machine-translated using Google Translate and may contain errors.